Retinal Disorder Treatment Market to see Rapid Growth by 2029
The global retinal disorder treatment market is anticipated to grow at a CAGR of 11.2% during the forecast period (2023-2030). Retinal disorders have both high prevalence and incidence in the geriatric population and diabetic patients, boosting the retinal disorder treatment market. According to the National Institute of Health (NIH), in April 2022, the major issue in the elderly population is the high prevalence of sight-threatening conditions, age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and cataracts. AMD is the leading cause of blindness in elderly patients in developed countries. In 2020, approximately 196 million people globally were affected by AMD, with a global prevalence of 8.7%. According to the latest predictions, the number of AMD patients will increase to 288 million people in 2040, as a consequence of the exponential increase in population ageing.
Geographic atrophy has a
devastating impact on patients' lives and can lead to irreversible vision loss.
For instance, in August 2023, Astellas Pharma Inc. announced the US (FDA)
approved IZERVAY™ (avacincaptad pegol intravitreal solution) for the treatment
of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
IZERVAY, a new complement C5 inhibitor, is the only approved GA treatment with
a statistically significant reduction (p<0.01) in the rate of GA progression
at the 12-month primary endpoint across two Phase 3 clinical trials.
Preclinical assets include an
intravitreally based program for dry age-related macular degeneration and a
program that targets cone-rod dystrophy. For instance, in June 2023, Beacon
Therapeutics launched retinal disease gene therapies. Beacon’s lead clinical
asset is AGTC-501, a gene therapy program in phase 2 clinical trials for the treatment
of X-linked retinitis pigmentosa (XLRP). Preclinical assets include therapies
for dry age-related macular degeneration and cone-rod dystrophy.
Retinopathy of prematurity is a
leading cause of childhood blindness globally. Mild cases of retinopathy of
prematurity (ROP) may improve without treatment, but some cases require
treatment to keep ROP from causing significant visual impairment and even
blindness. For instance, in February 2023, Regeneron Pharmaceuticals, Inc.
announced that the US FDA has approved EYLEA® (aflibercept) Injection to treat
preterm infants with retinopathy of prematurity. Following this first pediatric
approval, EYLEA was indicated to treat five retinal conditions caused by ocular
angiogenesis.
To Request a Sample of our Report on Retinal
Disorder Treatment Market: https://www.omrglobal.com/request-sample/retinal-disorder-treatment-market
•
The market number available for – 2022-2030
•
Base year- 2022
•
Forecast period- 2023-2030
Segment
Covered-
·
By Indication
·
By Dosage Form
·
By Distribution Channel
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
•
Competitive Landscape- includes Allergan, Inc.,
Bausch Health Companies Inc., Genentech, Inc., Novartis AG, and Regeneron
Pharmaceuticals, Inc., among others.
Retinal Disorder
Treatment Market Report Segment
By Indication
•
Diabetic Retinopathy
•
Macular Degeneration
•
Retinal Detachment
•
Retinoblastoma
•
Other (Diabetic Eye Disease, Macular Pucker, Macular
Hole, Floaters)
By Dosage Form
•
Gels
•
Eye Solutions
•
Capsules & Tablets
•
Eye Drops
•
Ointments
By Distribution Channel
•
Hospital Pharmacies
•
Retail Pharmacies
•
Online Sales
A full Report Retinal Disorder Treatment Market is
Available @ https://www.omrglobal.com/industry-reports/retinal-disorder-treatment-market
Retinal Disorder Treatment Market Report Segment by
Region
North America
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
•
Latin America
•
Middle East and Africa
Company Profiles
•
Adverum Biotechnologies
•
Aldeyra Therapeutics, Inc.
•
Alimera Sciences Inc.
•
Bausch Health Companies Inc.
•
Biogen Inc.
•
Clearside Biomedical, Inc.
•
F. Hoffmann-La Roche AG
•
Genentech, Inc.
•
Graybug Vision, Inc.
•
Gyroscope Therapeutics Holdings PLC
•
Iveric Bio, Inc.
•
Kala Pharmaceuticals
•
Kodiak Sciences
•
Otsuka Pharmaceutical Co Ltd.
•
Santen Pharmaceutical Co., Ltd.
•
Sentis Pharma Pvt Ltd.
•
Spark Therapeutics
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/retinal-disorder-treatment-market
About Orion Market Research
Orion Market
Research (OMR) is a market research and consulting company known for its crisp
and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services. The
company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services
through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment